|
|
 |
|
Viewing report
|
|
|
|
Biotech Investment and Business Trends: Weathering the Economic Storm
Decision Resources, Inc., June 2010, Pages: 33
After the disastrous stock market crash of 2008 and ensuing global economic crisis, the biotech industry is showing some signs of recovery. In 2009, overall fundraising was up and corporate partnering activity was robust. Although investors remain jittery, biotech stocks have been increasing since March 2009, giving more companies access to public equity. Nevertheless, factors such as economic volatility, healthcare reform, barriers to early-stage financing of innovation, and an increasingly hostile reimbursement environment are all contributing to uncertainty for the future of the biotech industry.
Questions answered in this report:
- The initial public offering (IPO) window cracked open in 2009 for the biotech industry. What types of therapeutic life sciences companies were able to go public in 2009? How much capital did they raise? What can companies expect from the 2010 public markets?
- Despite the ongoing impact of the recent economic downturn, venture capitalists (VCs) continued investing in biotech companies in 2009. What types of biotech companies are attracting VC investments? Which technologies are attracting the biggest VC investments?
- Although merger and acquisition (M&A) activity in 2009 was lower than many observers expected, biotech companies continued to merge and be acquired. What are the current trends in pharma-biotech and biotech-biotech M&As? What factors drove M&A activity in 2009? How has the structure of biotech M&As evolved in recent years?
- Corporate partnerships were the most reliable source of funding for the biotech industry in 2009. Are early-stage deals attracting significant investment from pharmaceutical companies? How are pharmaceutical companies reducing their level of risk in biotech licensing deals?
- Raising sufficient capital to support early-stage development programs is becoming increasingly difficult. What alternative financing and development strategies are available to biotech companies? What companies are implementing these alternatives?
- The ability to gain reimbursement of drugs is becoming an increasingly important factor for biotech. What impact will healthcare reform in the United States have on the biotech industry? How is the reimbursement environment changing?
Scope of the report:
- Public equity financing: The biotech IPO window; focus of IPO companies.
- Private equity financing: VC investment; focus of companies raising VC capital; high-value investments.
- Mergers and acquisitions: Trends in current high-value, strategic pharma-biotech, and biotech-biotech M&As; factors driving M&As; technologies of M&A companies.
- Corporate partnerships: Impact of the economic downturn; trends in corporate partnerships; option-based agreements; deal structures; area of focus for high-value alliances.
- Outlook for biotech investment and trends: Expectations for public and private equity financing and corporate partnering; alternative financing and development strategies; impact of healthcare reform; reimbursement of targeted therapies.
Key terms for this report:
Biotech industry, Biotechnology, Corporate alliance, Corporate partnership, Deals, Initial public offering (IPO), Licensing, Mergers and acquisitions (M&As), Private equity, Public equity, Strategic alliance, Venture capital, Virtualization
Customers who bought this item also bought
Biotech Investment and Business Trends: Surviving the Long Road to Market
Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?
Strategies for Building Biologics Capabilities and Franchises
Biotech 2011-Life Sciences: Looking Back to See Ahead
Biotechnology - Global Outlook
Success with Biobetters: Young Biobetters Companies and Pipelines
Biotechnology in India - An Indian Market Report
Biotech 2010 Life Sciences: Adapting for Success
US Biotech Market Analysis
Top 50 Biotechnology Companies & Their Pipelines 2010
|
|
|
|
